Fungal endocarditis accounts for 1% to 3% of all infective endocarditis cases, is associated
with high morbidity and mortality (> 70%), and presents numerous challenges during clinical …

Aspergillus fumigatus is one of the most ubiquitous of the airborne saprophytic fungi.
Humans and animals constantly inhale numerous conidia of this fungus. The conidia are …

It is important to realize that guidelines cannot always account for individual variation among
patients. They are not intended to supplant physician judgment with respect to particular …

The BSAC guidelines on treatment of infectious endocarditis (IE) were last published in
2004. The guidelines presented here have been updated and extended to reflect …

Major developments in research into the azole class of antifungal agents during the 1990s
have provided expanded options for the treatment of many opportunistic and endemic fungal …

To evaluate the efficacy and safety of voriconazole in acute invasive aspergillosis (IA), an
open, noncomparative multicenter study was conducted. Immunocompromised patients with …

Posaconazole, ravuconazole, and voriconazole are new triazole derivatives that possess
potent, broad-spectrum antifungal activity. We evaluated the in vitro activity of these …

During the past two decades invasive fungal infections have emerged as major causes of
morbidity and mortality in immunocompromised patients. Several factors have contributed to …

Voriconazole is a new triazole antifungal agent with potent, wide-spectrum activity. Its
pharmacokinetics and metabolism have been studied in mouse, rat, rabbit, dog, guinea pig …

Background: Reports of resistance and intolerance to currently available antifungal agents
are increasing. Voriconazole is a broad-spectrum azole antifungal agent structurally derived …